Per Svenningsson's research group

Translational Research on Neuropharmacology and Movement Disorders.

Parkinson's disease (PD) is a common disease where the basic pathophysiology is unclear. The next breakthrough in the treatment of PD should delay disease progression, based on insights into the underlying pathogenic process. The development of disease-modifying drugs is hampered by the lack of adequate diagnostics and biomarkers that reflect early signs of the disease.

For patients